| Metformin | Non metformin | Non diabetic | P-value | |||
---|---|---|---|---|---|---|---|
(n = 202) | (n = 184) | (n = 6,581) | |||||
Number | % | Number | % | Number | % | ||
Age at operation, years | Â | Â | Â | Â | Â | Â | Â |
 Median (range) | 55(10.5) |  | 59(10.2) |  | 46(9.6) |  | <0.001 |
 <50 | 68 | 33.7 | 40 | 21.7 | 4370 | 66.4 |  |
 ≥50 | 134 | 66.3 | 144 | 78.3 | 2211 | 33.6 |  |
Body mass index, kg/m 2 | Â | Â | Â | Â | Â | Â | Â |
 <18.5 | 0 | 0 | 4 | 2.2 | 242 | 3.7 | <0.001 |
 ≥18.5, <25 | 84 | 41.6 | 75 | 40.8 | 4644 | 70.8 |  |
 ≥25 | 118 | 58.4 | 105 | 57.1 | 1669 | 25.5 |  |
Serum glucose, mg/dL | Â | Â | Â | Â | Â | Â | Â |
 Median | 165.5 |  | 150.5 |  |  |  |  |
 ≤150 | 83 | 40.7 | 93 | 50 |  |  | 0.068 |
 >150 | 121 | 59.3 | 93 | 50 |  |  |  |
HbA1C, % | Â | Â | Â | Â | Â | Â | Â |
 <7 | 51 | 32.1 | 29 | 35.8 |  |  | 0.566 |
 ≥0.5108 | 67.9 | 52 | 64.2 |  |  |  |  |
Tumor size, cm | Â | Â | Â | Â | Â | Â | Â |
 ≤2 | 100 | 49.5 | 93 | 50.5 | 3535 | 53.7 | 0.356 |
 >2 | 102 | 50.5 | 91 | 49.5 | 3046 | 46.3 |  |
Node metastasis | Â | Â | Â | Â | Â | Â | Â |
 No | 110 | 54.5 | 110 | 59.8 | 3860 | 58.7 | 0.463 |
 Yes | 92 | 45.5 | 74 | 40.2 | 2721 | 41.3 |  |
Chemotherapy | Â | Â | Â | Â | Â | Â | Â |
 No | 66 | 32.7 | 80 | 43.5 | 1799 | 27.3 | <0.001 |
 Yes | 136 | 67.3 | 104 | 56.5 | 4782 | 72.7 |  |
Endocrine therapy | Â | Â | Â | Â | Â | Â | Â |
 No | 58 | 28.7 | 54 | 29.3 | 2013 | 30.6 | 0.801 |
 Yes | 144 | 71.3 | 130 | 70.7 | 4568 | 69.4 |  |
Subgroup according to IHC using ER, PR and HER2 | Â | Â | Â | Â | Â | Â | Â |
 Hormone receptor+, HER2- | 107 | 53.0 | 98 | 53.3 | 3390 | 51.5 | 0.385 |
 Hormone receptor+, HER2- | 27 | 13.4 | 18 | 9.8 | 916 | 13.9 |  |
 Hormone receptor-, HER2+ | 35 | 17.3 | 25 | 13.6 | 928 | 14.1 |  |
 Hormone receptor-, HER2- | 33 | 16.3 | 43 | 23.4 | 1347 | 20.5 |  |